November 5, 2021

Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology

Data Presented at ASH Underscores the Potential of the Smart-Immune Platform That Can Generate ex-vivo T- cell progenitors and NK- Cells for the Treatment of Primary Immunodeficiencies, and Cancers.